Mesenchymal stem cells rescue the Alzheimer's disease cell model from cell death induced by misfolded truncated tau

We have developed a stably transfected human cell model for Alzheimer's disease with doxycycline-inducible expression of human misfolded truncated tau protein (AT tau). We have showed that AT tau reduced the metabolic activity of the AT tau cells, slowed down cell proliferation, and induced caspase-3–independent apoptosis-like programmed cell death, tauoptosis. The aim of this study was to test the possible capability of rat mesenchymal stem cells (MSCs) to interfere with AT tau protein-induced cell death. AT tau cells after treatment with 10 μM all-trans retinoic acid were either co-cultivated with MSCs or supplemented with MSC secretome for 6 and 9 days. We found that both MSCs and MSC secretome promoted survival and increased the metabolic activity of the cells. Moreover stem cells induced cell differentiation and formation of neurites with numerous varicosities. Strikingly, treatment had no effect on tau expression suggesting that MSC induced self-protecting mechanism that prevented AT tau cells from tauoptosis. Our results showed that mesenchymal stem cells and their secretome are able to rescue the Alzheimer's disease cell model from cell death induced by misfolded truncated tau. We suggest that cell therapy may represent an alternative therapeutic avenue for treatment of human Alzheimer's disease and related tauopathies.

▶The expression of truncated tau in AD cells induced caspase-3–independent cell death, tauoptosis. ▶We found that mesenchymal stem cells and their secretome rescued the AD cells from the cell death. ▶The stem cells induced cell differentiation and led to the formation of neurites in AD cells. ▶The treatment had no effect on the expression of misfolded truncated tau. ▶We suggest that cell therapy may represent alternative therapeutic avenue for AD treatment.